ALFA Finder| Revenue guidance | 20.0% → 40.0% Raised by 20.0 percentage points |
|---|---|
| Management target | Revenue 30.0% FY28 |
| Revenue growth | Guided 25-30% YoY growth through FY30. |
|---|---|
| Margins | EBITDA margins expected to reach 30% as revenue hits ₹1,000Cr. |
| Demand visibility | Strong visibility from distributors in LATAM and MENA markets. |
| Management confidence | High; visibility from 60-70 new registrations and expansion plans. |
Growth
FY27 revenue guidance revised to ₹700Cr+ from ₹600Cr, implying 40% growth YoY; oncology currently contributes 20-25% of revenue.
Outlook
Targeting ₹1,500Cr revenue by FY30. ₹190Cr capex planned for hormone, oncology, and biosimilars; KPMG to be appointed auditor by Q4FY27.
Risks
Potential delays in international registrations and clinical trial timelines for biosimilars; elevated debtor days at 165-170 days.
Last quarter's promises, checked
Delivered
- Guided FY26 Revenue ₹500Cr+ → delivered ₹503Cr (= BEAT)
- Guided FY27 Revenue ₹650Cr → delivered ₹700Cr+ (= BEAT)
- Guided FY26 EBITDA Margin 22% → delivered 24% (= BEAT)
Partly delivered
- Guided Cash Conversion Cycle 208 days → delivered 170 days (= PARTIAL)
Earnings Call Transcript filed with BSE, NSE: KPL. Summary written with AI assistance from the document.
Kwality Pharmaceuticals Ltd: key numbers
- Share price
- ₹3,985.55
- Market cap
- ₹4,135 Cr
- Revenue (annual)
- ₹503.1 Cr
- Net profit (annual)
- ₹67.35 Cr
- P/E (TTM)
- 51.0×Sector 43.8×
- Promoter holding
- 54.86%+0.00% QoQ
- FII holding
- 2.50%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Kwality Pharmaceuticals Ltd
All →Kwality Pharmaceuticals Board Meeting Date
Kwality Pharmaceuticals will hold a board meeting on November 12, 2026. The board will consider and approve unaudited financial results for the quarter and half-year ended September 2026.
Kwality Pharmaceuticals Business Update
Kwality Pharmaceuticals secured EU-GMP approval from Hungary for its Cephalosporin and Oncology facilities. This expands its EU-approved manufacturing footprint and positions it for global licensing opportunities.
Kwality Pharmaceuticals Other Announcement
Kwality Pharmaceuticals Ltd filed its shareholding pattern for the quarter ended September 30, 2026, as required by SEBI regulations.
Kwality Pharmaceuticals Capacity Expansion
Kwality Pharmaceuticals acquired 4 acres adjacent to its Amritsar plant to build a fully automated facility with 10+ production lines. Completion is targeted by Q4 FY2028 with full operations by Q2 FY2029.
- Execution
- Completion by Q4 FY2028; full operations by Q2 FY2029
- manufacturing production lines (injectable + oral solid + ophthalmic)
- 10 production lines
Kwality Pharmaceuticals Management Change
Kwality Pharmaceuticals has regularized the appointment of Mr. Swanith Kapoor as Independent Director and reappointed Mr. Aditya Arora as Whole Time Director for five years.
Kwality Pharmaceuticals Annual General Meeting
Kwality Pharmaceuticals Limited conducted its 43rd Annual General Meeting on August 31, 2026, via video conferencing. The meeting covered routine shareholder resolutions and director re-appointments.